<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d2e4ebab-8c9d-44cb-b665-293007f7e058"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">PREDNISOLONE ORAL SOLUTION, USP 15 mg per 5 mL</content>
      <br/>
      <br/>
      <content styleCode="bold">Rx only</content>
   </title>
   <effectiveTime value="20250218"/>
   <setId root="b079834f-9aa3-4db9-bd53-de28e8f81c04"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="780779901"/>
            <name>Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="079394054"/>
                  <name>Chartwell RX, LLC</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="118673485"/>
                        <name>Chartwell Pharmaceuticals Carmel, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="23155-927" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="23155-927" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="23155-927" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="189630168"/>
                        <name>Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="23155-927" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="fcea4322-e9ac-4459-8d50-06295c3de2c1"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <title/>
               <text/>
               <effectiveTime value="20250211"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="23155-927" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Prednisolone</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>prednisolone oral solution</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="BUC5I9595W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CHERRY</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8SKN0B0MIM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZOIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS CITRIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="SB8ZUX40TY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SACCHARIN SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="15" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9PHQ9Y1OLM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PREDNISOLONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9PHQ9Y1OLM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PREDNISOLONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="240" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="23155-927-51" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250301"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="480" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="23155-927-52" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250301"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250301"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040323" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="pink" xsi:type="CE">
                              <originalText>clear pinkish-red</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73375" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CHERRY" xsi:type="CE">
                              <originalText>wild cherry</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="L05c7a63d-043e-4ad7-80c5-45f17dec6568">
               <id root="99fb44c7-a1c4-416b-9de2-fa5eb94b3f12"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Prednisolone oral solution contains prednisolone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisolone is a white to practically white, odorless, crystalline powder. It is very slightly soluble in water, soluble in methanol and in dioxane; sparingly soluble in acetone and in alcohol, slightly soluble in chloroform.<br/>The chemical name for Prednisolone is Pregna-1,4 -diene -3, 20 - dione, 11, 17, 21-trihydroxy-,(11β). Its molecular weight is 360.45. The molecular formula is C<sub>21</sub>H<sub>28</sub>O<sub>5</sub> and the structural formula is:</paragraph>
                  <paragraph>
                     <content>
                        <renderMultiMedia referencedObject="L19198ce7-ca56-4320-b1a6-bff76545b75e"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content>Prednisolone oral solution contains 15 mg of prednisolone in each 5 mL. Benzoic acid, 0.1% is added as a preservative. It also contains ethyl alcohol 5% (v/v), citric acid, edetate disodium, glycerin, propylene glycol, purified water, saccharin sodium, sucrose, natural and artificial wild cherry flavor, FD&amp;C red #40.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250218"/>
               <component>
                  <observationMedia ID="L19198ce7-ca56-4320-b1a6-bff76545b75e">
                     <text>Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lf70a6328-cbed-4600-8efb-194320d8e9c6">
               <id root="564dc841-2060-4542-ba08-2d741b80754d"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <text>
                  <paragraph>Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have saltretaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs such as prednisolone are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.<br/>Glucocorticoids such as prednisolone cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.</paragraph>
               </text>
               <effectiveTime value="20250210"/>
            </section>
         </component>
         <component>
            <section ID="L251fcdfb-e50d-4c7a-b881-bd08e60b14ad">
               <id root="9923592e-7cff-4a2f-ae39-304e1833f7d9"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>Prednisolone Oral Solution, USP is indicated in the following conditions:</paragraph>
               </text>
               <effectiveTime value="20250211"/>
               <component>
                  <section ID="La6452c01-edb8-485b-8fdd-d2edaa101588">
                     <id root="3544ca7a-dedd-47c1-ac3e-692be9b22a20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1. Endocrine Disorders</content>
                     </title>
                     <text>
                        <paragraph>Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).</paragraph>
                        <paragraph>
                           <content>      Congenital adrenal hyperplasia</content>
                           <br/>      Nonsuppurative thyroiditis<br/>      Hypercalcemia associated with cancer</paragraph>
                     </text>
                     <effectiveTime value="20250211"/>
                  </section>
               </component>
               <component>
                  <section ID="Ld4d25788-9a92-4913-99d0-bb9ac27b1f11">
                     <id root="aca8bf1f-eba2-4f8e-8957-21c849a1fa72"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2. Rheumatic Disorders</content>
                     </title>
                     <text>
                        <paragraph>As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:</paragraph>
                        <paragraph>      Psoriatic arthritis<br/>      Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)<br/>      Ankylosing spondylitis<br/>      Acute and subacute bursitis<br/>      Acute nonspecific tenosynovitis<br/>      Acute gouty arthritis<br/>      Post-traumatic osteoarthritis<br/>      Synovitis of osteoarthritis<br/>      Epicondylitis</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250211"/>
                  </section>
               </component>
               <component>
                  <section ID="L33195458-f5c1-4936-a495-6db5cbd794ff">
                     <id root="760daa16-2e79-4229-bd58-35a94ded1af4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">3. Collagen Diseases</content>
                     </title>
                     <text>
                        <paragraph>During an exacerbation or as maintenance therapy in selected cases of: </paragraph>
                        <paragraph>      Systemic lupus erythematosus<br/>      Acute rheumatic carditis</paragraph>
                     </text>
                     <effectiveTime value="20250211"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb47cfcd2-6890-4f46-bf46-e1f09d0528a1">
                     <id root="59cc6c41-f646-4123-a970-ce99d4a11746"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">4. Dermatologic Diseases</content>
                     </title>
                     <text>
                        <paragraph>      Pemphigus<br/>      Bullous dermatitis herpetiformis<br/>      Severe erythema multiforme (Stevens-Johnson syndrome)<br/>      Exfoliative dermatitis<br/>      Mycosis fungoides<br/>      Severe psoriasis<br/>      Severe seborrheic dermatitis</paragraph>
                     </text>
                     <effectiveTime value="20250210"/>
                  </section>
               </component>
               <component>
                  <section ID="L3c766e14-dfd1-487c-b229-c33f081677bc">
                     <id root="ed8a1a94-15d0-48e3-859d-19baa971e819"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5. Allergic States</content>
                     </title>
                     <text>
                        <paragraph>Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:</paragraph>
                        <paragraph>      Seasonal or perennial allergic rhinitis<br/>      Bronchial asthma<br/>      Contact dermatitis<br/>      Atopic dermatitis<br/>      Serum sickness<br/>      Drug hypersensitivity reactions</paragraph>
                     </text>
                     <effectiveTime value="20250210"/>
                  </section>
               </component>
               <component>
                  <section ID="L6f6b011e-1860-457f-b9bd-742bc8e92b8d">
                     <id root="729dca31-bf69-42b2-946d-abd033f91d31"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">6. Ophthalmic Diseases</content>
                     </title>
                     <text>
                        <paragraph>Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:  </paragraph>
                        <paragraph>      Allergic corneal marginal ulcers<br/>      Herpes zoster ophthalmicus<br/>      Anterior segment inflammation<br/>      Diffuse posterior uveitis and choroiditis<br/>      Sympathetic ophthalmia<br/>      Allergic conjunctivitis<br/>      Keratitis<br/>
                           <content>      Chorioretinitis</content>
                           <br/>      Optic neuritis<br/>      Iritis and iridocyclitis</paragraph>
                     </text>
                     <effectiveTime value="20250210"/>
                  </section>
               </component>
               <component>
                  <section ID="L1fe6e950-a4b3-4307-9b36-3300811cf208">
                     <id root="6d0d049f-4730-42a7-a160-c31c2565fad3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7. Respiratory Diseases</content>
                     </title>
                     <text>
                        <paragraph>Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means<br/>      Berylliosis<br/>      Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy<br/>      Aspiration pneumonitis</paragraph>
                     </text>
                     <effectiveTime value="20250210"/>
                  </section>
               </component>
               <component>
                  <section ID="L06f47b94-80a9-42d0-ac21-c0ffa3a230be">
                     <id root="2610a976-fdcd-46f3-97da-7abc765f0c39"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8. Hematologic Disorders</content>
                     </title>
                     <text>
                        <paragraph>Idiopathic thrombocytopenic purpura in adults<br/>Secondary thrombocytopenia in adults<br/>Acquired (autoimmune) hemolytic anemia<br/>Erythroblastopenia (RBC anemia)<br/>Congenital (erythroid) hypoplastic anemia</paragraph>
                     </text>
                     <effectiveTime value="20250210"/>
                  </section>
               </component>
               <component>
                  <section ID="L30b9dbab-5e4f-471e-b9b3-f9effcb24674">
                     <id root="5bb251a5-872f-4024-816e-0ca3732d0e45"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">9. Neoplastic Diseases</content>
                     </title>
                     <text>
                        <paragraph>For palliative management of:</paragraph>
                        <paragraph>      Acute leukemia of childhood<br/>      Leukemias and lymphomas in adults</paragraph>
                     </text>
                     <effectiveTime value="20250211"/>
                  </section>
               </component>
               <component>
                  <section ID="L1e569e17-82e6-4195-b479-d422938e2361">
                     <id root="f1385a6d-6bac-45eb-a2c4-6ba688c12a1e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">10. Edematous States</content>
                     </title>
                     <text>
                        <paragraph>To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.</paragraph>
                     </text>
                     <effectiveTime value="20250211"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf6988f85-02de-4f2e-9c78-0d55927bc6d7">
                     <id root="dd878065-2c17-4fc0-88a8-d9571ba51624"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">11. Gastrointestinal Diseases</content>
                     </title>
                     <text>
                        <paragraph>To tide the patient over a critical period of the disease in:</paragraph>
                        <paragraph>      Ulcerative colitis<br/>      Regional enteritis</paragraph>
                     </text>
                     <effectiveTime value="20250211"/>
                  </section>
               </component>
               <component>
                  <section ID="Le67695c7-bff2-4d97-91d8-974898207741">
                     <id root="5fb82376-b537-4a09-b417-2d8b6796ba35"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">12. Miscellaneous</content>
                     </title>
                     <text>
                        <paragraph>Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.<br/>In addition to the above indications prednisolone oral solution is indicated for systemic dermatomyositis (polymyositis).</paragraph>
                     </text>
                     <effectiveTime value="20250211"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lac7025eb-6f84-4811-b917-cd39f3e65250">
               <id root="74cddd4b-5728-471d-be92-210bbac6ddc2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>Systemic fungal infections.</paragraph>
               </text>
               <effectiveTime value="20250210"/>
            </section>
         </component>
         <component>
            <section ID="L797228d4-c82f-4c8d-88a3-4fac586522de">
               <id root="6bb0bb04-10de-407a-9a95-779a0656e8a7"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>
                  <content styleCode="bold">WARNINGS</content>
               </title>
               <text>
                  <paragraph> In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Immunosuppression and Increased Risk of Infection</content>
                  </paragraph>
                  <paragraph>Corticosteroids, including prednisolone oral solution, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can:</paragraph>
                  <list listType="unordered">
                     <item>Reduce resistance</item>
                     <item>Exacerbate existing infections</item>
                     <item>Increase the risk if disseminated infections</item>
                     <item>Increase the risk of reactivation or exacerbation of latent infections</item>
                     <item>Mask some signs of infection</item>
                  </list>
                  <paragraph>Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.</paragraph>
                  <paragraph>Monitor for the development of infection and consider prednisolone oral solution withdrawal or dosage reduction as needed.</paragraph>
                  <paragraph>Do not administer prednisolone oral solution by an intraarticular, intrabursal, intratendinous, or intralesional route in the presence of acute local infection.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Tuberculosis</content>
                     <br/>If prednisolone oral solution is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged prednisolone oral solution therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Varicella Zoster and Measles Viral Infections</content>
                  </paragraph>
                  <paragraph>Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including prednisolone oral solution. In corticosteroids-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles:</paragraph>
                  <list listType="unordered">
                     <item>If a prednisolone oral solution-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.</item>
                     <item>If a prednisolone oral solution-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.</item>
                  </list>
                  <paragraph>
                     <content styleCode="italics">Hepatitis B Virus Reactivation</content>
                     <br/>Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including prednisolone oral solution. Reactivation can also occur infrequently in corticosteroids-treated patients who appear to have resolved hepatitis B infection.</paragraph>
                  <paragraph>Screen patients for hepatitis B infection before initiating immunosuppressive (e.g. prolonged) treatment with prednisolone oral solution. For patients who show evidence of hepatitis B infection, recommend consultation with physician with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Fungal Infections</content>
                     <br/>Corticosteroids, including prednisolone oral solution, may exacerbate systemic fungal infections; therefore, avoid prednisolone oral solution use in the presence of such infections unless prednisolone oral solution is needed to control drug reactions. For patients on chronic prednisolone oral solution therapy who develop systemic fungal infections, prednisolone oral solution withdrawal or dosage reduction is recommended.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Amebiasis</content>
                     <br/>Corticosteroids, including prednisolone oral solution, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating prednisolone oral solution in patients who spent time in the tropics or patients with unexplained diarrhea.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Strongyloides Infestation</content>
                     <br/>Corticosteroids, including prednisolone oral solution, should be used with great care in patients with known or suspected Stronyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Cerebral Malaria</content>
                     <br/>Avoid corticosteroids, including prednisolone oral solution, in patients with cerebral malaria.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Kaposi’s Sarcoma</content>
                     <br/>Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroids therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma.</paragraph>
                  <paragraph>Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.</paragraph>
                  <paragraph>Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</paragraph>
                  <paragraph>While on corticosteroid therapy, patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Use in pregnancy:</content> Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.</paragraph>
               </text>
               <effectiveTime value="20250211"/>
            </section>
         </component>
         <component>
            <section ID="L0025a496-ca95-4186-9616-49ba537cc6c1">
               <id root="e5fdc12c-3c45-4a37-b0a6-850ccd54dffd"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">PRECAUTIONS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">General</content>
                     <br/>Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.</paragraph>
                  <paragraph>There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.</paragraph>
                  <paragraph>Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.</paragraph>
                  <paragraph>The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.</paragraph>
                  <paragraph>Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.</paragraph>
                  <paragraph>
                     <br/>Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.</paragraph>
                  <paragraph>Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infections; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.</paragraph>
                  <paragraph>Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.</paragraph>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Information for Patients</content>
                     <br/>Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</paragraph>
               </text>
               <effectiveTime value="20250211"/>
            </section>
         </component>
         <component>
            <section ID="L28e795f4-ea90-4976-a8b3-65dd90000cc9">
               <id root="cb2c6aef-2e8a-4f2a-b698-4779e29639e3"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Fluid and Electrolyte Disturbances</content>
                     <br/>      Sodium retention<br/>      Fluid retention<br/>      Congestive heart failure in susceptible patients<br/>      Potassium loss<br/>      Hypokalemic alkalosis<br/>      Hypertension<br/>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Musculoskeletal</content>
                     <br/>      Muscle weakness<br/>      Steroid myopathy<br/>      Loss of muscle mass<br/>      Osteoporosis<br/>      Vertebral compression fractures<br/>      Aseptic necrosis of femoral and humeral heads<br/>      Pathologic fracture of long bones</paragraph>
                  <paragraph>
                     <content styleCode="bold">Gastrointestinal</content>
                     <br/>      Peptic ulcer with possible perforation and hemorrhage<br/>      Pancreatitis<br/>      Abdominal distention<br/>      Ulcerative esophagitis<br/>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dermatologic</content>
                     <br/>      Impaired wound healing<br/>      Thin fragile skin<br/>      Petechiae and ecchymoses<br/>      Facial erythema<br/>      Increased sweating<br/>      May suppress reactions to skin tests<br/>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Neurological</content>
                  </paragraph>
                  <paragraph>      Convulsions <br/>
                     <content>      Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment</content>
                     <br/>
                     <content>      Vertigo</content>
                     <br/>      Headache</paragraph>
                  <paragraph>
                     <content/>
                  </paragraph>
                  <paragraph>
                     <content/>
                  </paragraph>
                  <paragraph>
                     <content>
                        <content styleCode="bold"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content>
                        <content styleCode="bold">Endocrine</content>
                        <br/>      Menstrual irregularities<br/>      Development of Cushingoid state<br/>      Suppression of growth in children<br/>      Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness<br/>      Decreased carbohydrate tolerance<br/>      Manifestations of latent diabetes mellitus<br/>      Increased requirements for insulin or oral hypoglycemic agents in diabetics<br/>
                        <content styleCode="bold"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content>
                        <content styleCode="bold">Ophthalmic</content>
                        <br/>      Posterior subcapsular cataracts<br/>      Increased intraocular pressure<br/>      Glaucoma<br/>      Exophthalmos<br/>
                        <content styleCode="bold"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content>
                        <content styleCode="bold">Metabolic</content>
                        <br/>      Negative nitrogen balance due to protein catabolism</content>
                  </paragraph>
                  <paragraph>
                     <content>To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250210"/>
            </section>
         </component>
         <component>
            <section ID="L27996bc0-b322-4ebe-ae1d-1df10e4ada2d">
               <id root="f34e5d29-e9ad-4b19-bb32-18b6e1471e7c"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <text>
                  <paragraph>Dosage of Prednisolone Oral Solution, USP should be individualized according to the severity of the disease and the response of the patient. For infants and children, the recommended dosage should be governed by the same considerations rather than strict adherence to the ratio indicated by age or body weight.</paragraph>
                  <paragraph>Hormone therapy is an adjunct to and not a replacement for conventional therapy.</paragraph>
                  <paragraph>Dosage should be decreased or discontinued gradually when the drug has been administered for more than a few days.</paragraph>
                  <paragraph>The severity, prognosis, expected duration of the disease, and the reaction of the patient to medication are primary factors in determining dosage.</paragraph>
                  <paragraph>If a period of spontaneous remission occurs in a chronic condition, treatment should be discontinued. </paragraph>
                  <paragraph>Blood pressure, body weight, routine laboratory studies, including two-hour postprandial blood glucose and serum potassium, and a chest X-ray should be obtained at regular intervals during prolonged therapy. Upper GI X-rays are desirable in patients with known or suspected peptic<br/>ulcer disease.</paragraph>
                  <paragraph>The initial dosage of Prednisolone Oral Solution, USP may vary from 5 mg to 60 mg per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Prednisolone Oral Solution, USP should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.</paragraph>
                  <paragraph>After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of Prednisolone Oral Solution, USP for a period of time consistent with the patient’s condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.</paragraph>
               </text>
               <effectiveTime value="20250211"/>
            </section>
         </component>
         <component>
            <section ID="Ld745faff-5830-4b0e-969a-bfaa863987da">
               <id root="e4438342-03fb-47bc-a2e6-bf43451a97dd"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">HOW SUPPLIED</content>
               </title>
               <text>
                  <paragraph>Prednisolone Oral Solution, USP containing 15 mg of Prednisolone in each 5 mL (teaspoonful) is a clear pinkish-red wild cherry flavored liquid and is supplied in 240 mL bottles (NDC 23155-927-51), 480 mL (NDC 23155-927-52) bottles.</paragraph>
                  <paragraph>Pharmacist: Dispense 15 mg/5 mL Prednisolone Oral Solution, USP with suitable calibrated measuring device to assure proper measuring of dose.</paragraph>
                  <paragraph>
                     <content>
                        <renderMultiMedia referencedObject="Ld4efebea-15bd-444c-898d-833efe342d5c"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content>Dispense in tight, light-resistant and child-resistant container as defined in USP/NF.</content>
                  </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. DO NOT REFRIGERATE.</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Avet Pharmaceuticals Inc.</content>
                     <br/>East Brunswick, NJ 08816<br/>1.866.901.DRUG (3784)</paragraph>
                  <paragraph>
                     <content>
                        <renderMultiMedia referencedObject="L86458fa3-7724-4a3b-849f-39f565adc02d"/>
                     </content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Revised: 01/2025</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250218"/>
               <component>
                  <observationMedia ID="L86458fa3-7724-4a3b-849f-39f565adc02d">
                     <text>avet logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="avet logo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Ld4efebea-15bd-444c-898d-833efe342d5c">
                     <text>how supply</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="how supply.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="La3b94e69-15cd-4463-9467-1e074e397aa5">
               <id root="3dc49032-753a-491a-ade9-69343cbb2c45"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">PrednisoLONE Oral Solution, USP 15 mg per 5 mL - NDC 23155-927-51- 240 mL Bottle Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L7ab8635e-846c-4b58-8bbb-fb538e333048"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PrednisoLONE Oral Solution, USP 15 mg per 5 mL - NDC 23155-927-52- 480 mL Bottle Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L185fc9d7-d2f6-4dd3-aa31-eb8418a7426a"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250211"/>
               <component>
                  <observationMedia ID="L7ab8635e-846c-4b58-8bbb-fb538e333048">
                     <text>240 ml</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="240 ml.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L185fc9d7-d2f6-4dd3-aa31-eb8418a7426a">
                     <text>480ml</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="480ml.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>